Impact of Stem Cell Donation on Unrelated and Related Donors' Health.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-02-03

Study Completion Date

2029-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Haematopoietic stem cell donation represents a unique chance for curing patients affected with onchohaematologic and inherited diseases.If a related donor is unavailable a unrelated donor must be used. For both categories an accurate physical and laboratory examination is mandatory to establish the eligibility to bone marrow or peripheral blood stem cell collection since side effects related to donation may occur. To ensure high standards of safety and satisfaction of unrelated stem cells donors dedicated guidelines are available. On the other hand, there is no unambiguous guidance on the management of the related donor and published data on donation and long term follow-up are scarce.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Occupational Status and Hematological Disease

NCT02057185

Chronic Myeloid Leukemia Chronic Lymphocytic Leukemia Myelodysplastic Syndrome +2 more

COMPLETED

Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant

NCT05722210

Hematopoietic Stem Cell Transplant

NOT_YET_RECRUITING

Mobilization and Handling of Stem Cells for Transplant From Healthy Volunteers With Sickle Cell Trait

NCT00005782

Sickle Cell Trait

COMPLETED PHASE3

Improving Blood Stem Cell Collection and Transplant Procedures

NCT01517035

Myelodysplastic Syndrome (MDS) Chronic Myelogenous Leukemia Acute Lymphoblastic Leukemia +2 more

COMPLETED PHASE1/PHASE2

Mesenchymal Stem Cells for the Treatment of Pneumonia Post Haematopoietic Stem Cell Transplantation

NCT05131412

Pneumonia Hematopoietic Stem Cell Transplantation

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study, for the retrospective part, aims to report the experience in family and registry donor management at Transfusion Service from 2016 to 2022 (enrollment, stem cell donation, 30-day follow-up) and, for the prospective part, to continue monitoring on donors who will be enrolled in the next five years (2023 to 2028).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stem Cell Donors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Family donors ≥18 years referred by the Hematology and Oncohematology Transplant Center Pediatric of the Foundation of Centro Donatori -SIMT, following the national and international guidelines after medical evaluation
* Volunteer donors from IBMDR registry ≥18 years, following the national and international guidelines after medical evaluation